Mesoblast Limited

MSB

AU000000MSB8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:26 2026-04-10 am EDT			5-day change	1st Jan Change
2.120 ^AUD	+4.43%		-0.47%	-22.06%

Apr. 10	Mesoblast Gets US FDA Clearance to Proceed to Registrational Trial for Ryoncil in Duchenne Muscular Dystrophy	MT
Apr. 09	Mesoblast's Fiscal 2026 Net Revenue Projected to be Up to $120 Million, Jefferies Says	MT

Mesoblast Limited Provides Revenue Guidance for Fiscal Year 2026

Published on 02/26/2026 at 11:50 pm EST

S&P Capital IQ

MESOBLAST LIMITED

+4.43%

Mesoblast Limited provided revenue guidance for fiscal year 2026. Mesoblast anticipates full-year fiscal 2026 Ryoncil net revenue to range between USD 110 million and USD 120 million.

Latest news about Mesoblast Limited

Apr. 10	Mesoblast Gets US FDA Clearance to Proceed to Registrational Trial for Ryoncil in Duchenne Muscular Dystrophy	MT
Apr. 09	Mesoblast's Fiscal 2026 Net Revenue Projected to be Up to $120 Million, Jefferies Says	MT
Apr. 09	Cardiff Oncology, Inc. Appoints Josh Muntner as Chief Financial Officer, Effective April 6, 2026	CI
Apr. 08	Mesoblast Limited - Special Call
Apr. 08	Mesoblast's Duchenne Muscular Dystrophy Treatment Heads for US Registrational Clinical Trial; Shares Up Pre-Bell	MT
Apr. 08	Mesoblast Limited Receives IND Clearance From FDA To Proceed To Registrational Trial For Ryoncil In Duchenne Muscular Dystrophy	CI
Apr. 07	Mesoblast Secures FDA Investigational New Drug Clearance for Registrational Clinical Trial for Ryoncil Product in Duchenne Muscular Dystrophy	MT
Apr. 07	Mesoblast Reports Ryoncil Net Sales for March Quarter	MT
Apr. 06	Mesoblast Reports Ryoncil Net Sales of Over $30 Million in March Quarter	MT
Apr. 06	Mesoblast says Ryoncil's net revenue for quarter increases to US$30.3m	RE
Mar. 12	Mesoblast Limited Appoints Dr. Teresa Montagut As Head Of Clinical Development And Medical Affairs	CI
Mar. 11	Mesoblast Appoints Head of Clinical Development, Medical Affairs	MT
Mar. 09	Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys	MT
Mar. 01	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
Feb. 26	Mesoblast Limited Provides Revenue Guidance for Fiscal Year 2026	CI

Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.

Employees

Sector

Biotechnology & Medical Research

More about the company